Cargando…

Analysis of tumor-infiltrating NK and T cells highlights IL-15 stimulation and TIGIT blockade as a combination immunotherapy strategy for soft tissue sarcomas

PURPOSE: Given the unmet need for novel immunotherapy in soft tissue sarcoma (STS), we sought to characterize the phenotype and function of intratumoral natural killer (NK) and T cells to identify novel strategies to augment tumor-infiltrating lymphocyte (TIL) function. EXPERIMENTAL DESIGN: Using pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Judge, Sean J, Darrow, Morgan A, Thorpe, Steve W, Gingrich, Alicia A, O'Donnell, Edmond F, Bellini, Alyssa R, Sturgill, Ian R, Vick, Logan V, Dunai, Cordelia, Stoffel, Kevin M, Lyu, Yue, Chen, Shuai, Cho, May, Rebhun, Robert B, Monjazeb, Arta M, Murphy, William J, Canter, Robert J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7651745/
https://www.ncbi.nlm.nih.gov/pubmed/33158916
http://dx.doi.org/10.1136/jitc-2020-001355
_version_ 1783607590504103936
author Judge, Sean J
Darrow, Morgan A
Thorpe, Steve W
Gingrich, Alicia A
O'Donnell, Edmond F
Bellini, Alyssa R
Sturgill, Ian R
Vick, Logan V
Dunai, Cordelia
Stoffel, Kevin M
Lyu, Yue
Chen, Shuai
Cho, May
Rebhun, Robert B
Monjazeb, Arta M
Murphy, William J
Canter, Robert J
author_facet Judge, Sean J
Darrow, Morgan A
Thorpe, Steve W
Gingrich, Alicia A
O'Donnell, Edmond F
Bellini, Alyssa R
Sturgill, Ian R
Vick, Logan V
Dunai, Cordelia
Stoffel, Kevin M
Lyu, Yue
Chen, Shuai
Cho, May
Rebhun, Robert B
Monjazeb, Arta M
Murphy, William J
Canter, Robert J
author_sort Judge, Sean J
collection PubMed
description PURPOSE: Given the unmet need for novel immunotherapy in soft tissue sarcoma (STS), we sought to characterize the phenotype and function of intratumoral natural killer (NK) and T cells to identify novel strategies to augment tumor-infiltrating lymphocyte (TIL) function. EXPERIMENTAL DESIGN: Using prospectively collected specimens from dogs and humans with sarcomas, archived specimens, and The Cancer Genome Atlas (TCGA) data, we evaluated blood and tumor NK and T cell phenotype and function and correlated those with outcome. We then assessed the effects of interleukin 15 (IL-15) stimulation on both NK and T cell activation and TIGIT upregulation. Finally, we evaluated cytotoxic effects of IL-15 combined with TIGIT blockade using a novel anti-TIGIT antibody. RESULTS: TILs were strongly associated with survival outcome in both archived tissue and TCGA, but higher TIL content was also associated with higher TIGIT expression. Compared with blood, intratumoral NK and T cells showed significantly higher expression of both activation and exhaustion markers, in particular TIGIT. Ex vivo stimulation of blood and tumor NK and T cells from patients with STS with IL-15 further increased both activation and exhaustion markers, including TIGIT. Dogs with metastatic osteosarcoma receiving inhaled IL-15 also exhibited upregulation of activation markers and TIGIT. Ex vivo, combined IL-15 and TIGIT blockade using STS blood and tumor specimens significantly increased cytotoxicity against STS targets. CONCLUSION: Intratumoral NK and T cells are prognostic in STS, but their activation is marked by significant upregulation of TIGIT. Our data suggest that combined IL-15 and TIGIT blockade may be a promising clinical strategy in STS.
format Online
Article
Text
id pubmed-7651745
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-76517452020-11-17 Analysis of tumor-infiltrating NK and T cells highlights IL-15 stimulation and TIGIT blockade as a combination immunotherapy strategy for soft tissue sarcomas Judge, Sean J Darrow, Morgan A Thorpe, Steve W Gingrich, Alicia A O'Donnell, Edmond F Bellini, Alyssa R Sturgill, Ian R Vick, Logan V Dunai, Cordelia Stoffel, Kevin M Lyu, Yue Chen, Shuai Cho, May Rebhun, Robert B Monjazeb, Arta M Murphy, William J Canter, Robert J J Immunother Cancer Clinical/Translational Cancer Immunotherapy PURPOSE: Given the unmet need for novel immunotherapy in soft tissue sarcoma (STS), we sought to characterize the phenotype and function of intratumoral natural killer (NK) and T cells to identify novel strategies to augment tumor-infiltrating lymphocyte (TIL) function. EXPERIMENTAL DESIGN: Using prospectively collected specimens from dogs and humans with sarcomas, archived specimens, and The Cancer Genome Atlas (TCGA) data, we evaluated blood and tumor NK and T cell phenotype and function and correlated those with outcome. We then assessed the effects of interleukin 15 (IL-15) stimulation on both NK and T cell activation and TIGIT upregulation. Finally, we evaluated cytotoxic effects of IL-15 combined with TIGIT blockade using a novel anti-TIGIT antibody. RESULTS: TILs were strongly associated with survival outcome in both archived tissue and TCGA, but higher TIL content was also associated with higher TIGIT expression. Compared with blood, intratumoral NK and T cells showed significantly higher expression of both activation and exhaustion markers, in particular TIGIT. Ex vivo stimulation of blood and tumor NK and T cells from patients with STS with IL-15 further increased both activation and exhaustion markers, including TIGIT. Dogs with metastatic osteosarcoma receiving inhaled IL-15 also exhibited upregulation of activation markers and TIGIT. Ex vivo, combined IL-15 and TIGIT blockade using STS blood and tumor specimens significantly increased cytotoxicity against STS targets. CONCLUSION: Intratumoral NK and T cells are prognostic in STS, but their activation is marked by significant upregulation of TIGIT. Our data suggest that combined IL-15 and TIGIT blockade may be a promising clinical strategy in STS. BMJ Publishing Group 2020-11-06 /pmc/articles/PMC7651745/ /pubmed/33158916 http://dx.doi.org/10.1136/jitc-2020-001355 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Clinical/Translational Cancer Immunotherapy
Judge, Sean J
Darrow, Morgan A
Thorpe, Steve W
Gingrich, Alicia A
O'Donnell, Edmond F
Bellini, Alyssa R
Sturgill, Ian R
Vick, Logan V
Dunai, Cordelia
Stoffel, Kevin M
Lyu, Yue
Chen, Shuai
Cho, May
Rebhun, Robert B
Monjazeb, Arta M
Murphy, William J
Canter, Robert J
Analysis of tumor-infiltrating NK and T cells highlights IL-15 stimulation and TIGIT blockade as a combination immunotherapy strategy for soft tissue sarcomas
title Analysis of tumor-infiltrating NK and T cells highlights IL-15 stimulation and TIGIT blockade as a combination immunotherapy strategy for soft tissue sarcomas
title_full Analysis of tumor-infiltrating NK and T cells highlights IL-15 stimulation and TIGIT blockade as a combination immunotherapy strategy for soft tissue sarcomas
title_fullStr Analysis of tumor-infiltrating NK and T cells highlights IL-15 stimulation and TIGIT blockade as a combination immunotherapy strategy for soft tissue sarcomas
title_full_unstemmed Analysis of tumor-infiltrating NK and T cells highlights IL-15 stimulation and TIGIT blockade as a combination immunotherapy strategy for soft tissue sarcomas
title_short Analysis of tumor-infiltrating NK and T cells highlights IL-15 stimulation and TIGIT blockade as a combination immunotherapy strategy for soft tissue sarcomas
title_sort analysis of tumor-infiltrating nk and t cells highlights il-15 stimulation and tigit blockade as a combination immunotherapy strategy for soft tissue sarcomas
topic Clinical/Translational Cancer Immunotherapy
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7651745/
https://www.ncbi.nlm.nih.gov/pubmed/33158916
http://dx.doi.org/10.1136/jitc-2020-001355
work_keys_str_mv AT judgeseanj analysisoftumorinfiltratingnkandtcellshighlightsil15stimulationandtigitblockadeasacombinationimmunotherapystrategyforsofttissuesarcomas
AT darrowmorgana analysisoftumorinfiltratingnkandtcellshighlightsil15stimulationandtigitblockadeasacombinationimmunotherapystrategyforsofttissuesarcomas
AT thorpestevew analysisoftumorinfiltratingnkandtcellshighlightsil15stimulationandtigitblockadeasacombinationimmunotherapystrategyforsofttissuesarcomas
AT gingrichaliciaa analysisoftumorinfiltratingnkandtcellshighlightsil15stimulationandtigitblockadeasacombinationimmunotherapystrategyforsofttissuesarcomas
AT odonnelledmondf analysisoftumorinfiltratingnkandtcellshighlightsil15stimulationandtigitblockadeasacombinationimmunotherapystrategyforsofttissuesarcomas
AT bellinialyssar analysisoftumorinfiltratingnkandtcellshighlightsil15stimulationandtigitblockadeasacombinationimmunotherapystrategyforsofttissuesarcomas
AT sturgillianr analysisoftumorinfiltratingnkandtcellshighlightsil15stimulationandtigitblockadeasacombinationimmunotherapystrategyforsofttissuesarcomas
AT vickloganv analysisoftumorinfiltratingnkandtcellshighlightsil15stimulationandtigitblockadeasacombinationimmunotherapystrategyforsofttissuesarcomas
AT dunaicordelia analysisoftumorinfiltratingnkandtcellshighlightsil15stimulationandtigitblockadeasacombinationimmunotherapystrategyforsofttissuesarcomas
AT stoffelkevinm analysisoftumorinfiltratingnkandtcellshighlightsil15stimulationandtigitblockadeasacombinationimmunotherapystrategyforsofttissuesarcomas
AT lyuyue analysisoftumorinfiltratingnkandtcellshighlightsil15stimulationandtigitblockadeasacombinationimmunotherapystrategyforsofttissuesarcomas
AT chenshuai analysisoftumorinfiltratingnkandtcellshighlightsil15stimulationandtigitblockadeasacombinationimmunotherapystrategyforsofttissuesarcomas
AT chomay analysisoftumorinfiltratingnkandtcellshighlightsil15stimulationandtigitblockadeasacombinationimmunotherapystrategyforsofttissuesarcomas
AT rebhunrobertb analysisoftumorinfiltratingnkandtcellshighlightsil15stimulationandtigitblockadeasacombinationimmunotherapystrategyforsofttissuesarcomas
AT monjazebartam analysisoftumorinfiltratingnkandtcellshighlightsil15stimulationandtigitblockadeasacombinationimmunotherapystrategyforsofttissuesarcomas
AT murphywilliamj analysisoftumorinfiltratingnkandtcellshighlightsil15stimulationandtigitblockadeasacombinationimmunotherapystrategyforsofttissuesarcomas
AT canterrobertj analysisoftumorinfiltratingnkandtcellshighlightsil15stimulationandtigitblockadeasacombinationimmunotherapystrategyforsofttissuesarcomas